Last updated: September 8, 2026
Basic Care Lansoprazole is an over-the-counter, small-molecule proton-pump inhibitor product containing lansoprazole, generally marketed as a 15 mg delayed-release capsule. Its commercial value depends less on active-ingredient exclusivity and more on manufacturing cost, enteric-release performance, shelf stability, private-label distribution, packaging, and differentiated dosage forms.
The product category has low compound-patent risk because the original lansoprazole patents expired years ago. The main technical barrier is reproducible delayed release: the formulation must protect lansoprazole from gastric acid and deliver dissolution in the intestinal environment. FDA labeling for OTC lansoprazole requires a 24-hour heartburn indication and specific consumer-use restrictions. [1][2]
What is Basic Care Lansoprazole?
Basic Care Lansoprazole is an OTC acid-reducer product sold under Amazon’s Basic Care private-label portfolio. Public product labeling identifies lansoprazole as the active ingredient and uses a delayed-release capsule presentation. The common OTC strength is 15 mg per capsule.
| Attribute |
Product profile |
| Brand |
Basic Care |
| Active ingredient |
Lansoprazole |
| Drug class |
Proton-pump inhibitor |
| Typical strength |
15 mg |
| Dosage form |
Delayed-release capsule |
| Administration |
Oral |
| OTC indication |
Frequent heartburn, generally occurring two or more days per week |
| Release requirement |
Delayed release with protection through the stomach |
| Regulatory pathway |
OTC product supported by an FDA-approved lansoprazole application or applicable FDA regulatory pathway |
| Biosimilar exposure |
None; lansoprazole is a synthetic small molecule |
| Primary commercial competitors |
Prevacid 24HR, generic lansoprazole, store-brand PPIs, omeprazole, esomeprazole, and famotidine products |
The exact manufacturer, National Drug Code, capsule supplier, and current inactive-ingredient declaration can vary by package and supply arrangement. FDA labeling and DailyMed records should control product-specific conclusions. [1][3]
What excipients are used in lansoprazole delayed-release capsules?
Lansoprazole delayed-release capsules commonly contain multiparticulate pellets rather than a single unprotected powder fill. The excipient system normally includes an inert core, drug-containing layer, protective seal coat, enteric coating, and capsule shell.
Common excipient functions include:
| Excipient category |
Typical function in lansoprazole capsules |
| Sugar spheres or inert cores |
Provide a uniform substrate for drug layering |
| Hypromellose |
Binder and protective film former |
| Alkalinizing agent, such as magnesium carbonate |
Helps stabilize lansoprazole against acid degradation |
| Methacrylic acid copolymer |
Enteric coating that dissolves at higher intestinal pH |
| Talc |
Anti-tacking and coating-process aid |
| Polyethylene glycol |
Plasticizer and film-coating modifier |
| Polysorbate 80 |
Wetting or dispersion aid |
| Titanium dioxide and colorants |
Capsule or coating appearance |
| Gelatin or hypromellose capsule shell |
Encapsulation of the coated pellets |
| Sodium hydroxide |
pH adjustment during coating or drug-layer preparation |
| Starch or other fillers |
Processing and bulk-volume control |
The exact formulation should not be inferred solely from the active ingredient. FDA-approved lansoprazole products can use different pellet cores, stabilizers, coating weights, capsule materials, and manufacturing processes while meeting the same dissolution and bioequivalence requirements. [3][4]
How does the excipient system protect lansoprazole?
Lansoprazole is acid-labile. Exposure to gastric acid can cause degradation before the active ingredient reaches its absorption site. The formulation therefore requires a basic microenvironment and an enteric barrier.
The typical release architecture is:
- The drug is deposited on inert pellets or another multiparticulate core.
- An alkaline component limits acid-driven degradation around the drug.
- A seal coat separates the drug layer from the enteric polymer.
- The enteric coat resists low gastric pH.
- The coat dissolves in the higher-pH intestinal environment.
- Lansoprazole is released for absorption after gastric transit.
This architecture creates several manufacturing sensitivities:
- Drug-layer uniformity across pellet batches.
- Control of alkalinizing-agent distribution.
- Enteric-coat weight gain and film continuity.
- Moisture exposure during coating and encapsulation.
- Pellet attrition during blending and filling.
- Capsule dissolution after storage.
- Lot-to-lot consistency in acid resistance and buffer-stage release.
For a private-label product, the most important excipient strategy is usually not novelty. It is robust process control using widely available materials with established pharmaceutical supply chains.
What formulation patents protect lansoprazole products?
The original lansoprazole compound and early pharmaceutical-composition patents are expired or no longer meaningful barriers to ordinary generic entry in the United States.
| Patent category |
Commercial relevance |
| Original lansoprazole compound patents |
Expired |
| Early delayed-release composition patents |
Generally expired |
| Basic enteric-coated pellet technology |
Largely available for generic development, subject to claim-by-claim review |
| Product-specific formulation patents |
Potentially relevant only if unexpired and listed or asserted |
| Manufacturing-process patents |
May create narrow process risk but usually do not block all generic formulations |
| Method-of-use patents |
Limited relevance for standard OTC heartburn labeling unless an enforceable claim covers the intended use |
The original Prevacid product was approved under FDA application NDA 21-229. The FDA Orange Book records patent and exclusivity information for listed products, but an Orange Book search must be performed against the specific reference product, dosage form, and current patent listings. [1][5]
A generic or private-label sponsor cannot rely solely on the absence of an active compound patent. It must assess formulation, process, polymorph, impurity, packaging, and method-of-use claims held by competitors or suppliers. For a standard 15 mg delayed-release capsule, the practical freedom-to-operate burden is usually narrower than for a novel delivery system.
When does lansoprazole lose exclusivity?
Lansoprazole lost meaningful market exclusivity long before the launch of current store-brand and private-label products.
The relevant timeline is:
| Event |
Approximate timing |
| Original lansoprazole development and patenting |
1980s |
| U.S. approval of Prevacid |
1995 |
| OTC Prevacid 24HR approval |
2009 |
| Original compound and early formulation patent barriers |
Expired by the late 2000s |
| Generic and store-brand competition |
Established |
| Current commercial position |
Mature OTC category with low active-ingredient exclusivity |
Current market protection is therefore based on brand recognition, retail placement, supply economics, formulation quality, and package architecture rather than a live compound monopoly.
What is the FDA regulatory status of Basic Care Lansoprazole?
Lansoprazole is an FDA-approved OTC proton-pump inhibitor. OTC PPIs are subject to detailed labeling, dosage, warning, and use restrictions. The relevant FDA framework includes the approved lansoprazole reference product and FDA requirements governing OTC acid-reducing products. [1][2]
Key regulatory considerations include:
- The product must use compliant Drug Facts labeling.
- The OTC indication is intended for frequent heartburn rather than undifferentiated abdominal symptoms.
- The label includes age, dosing, duration-of-use, and warning limitations.
- Consumers are directed to seek medical advice for alarm symptoms or persistent symptoms.
- Delayed-release performance must be demonstrated through product specifications and stability data.
- Manufacturing must comply with current good manufacturing practice requirements.
- Changes to excipients, coating process, capsule shell, or release profile may require regulatory assessment.
A private-label owner can market an approved or appropriately authorized product without owning the original lansoprazole intellectual property. The commercial arrangement normally depends on a contract manufacturer, application holder, or authorized supplier that carries the relevant regulatory responsibility.
Are Paragraph IV challenges relevant to Basic Care Lansoprazole?
Paragraph IV litigation is mainly relevant during generic approval of a product protected by unexpired Orange Book patents. For a mature lansoprazole delayed-release capsule, Paragraph IV risk is materially lower than it was during the original generic-entry period.
Potential Paragraph IV issues could still arise if a reference product has:
- A later-issued formulation patent.
- A patent directed to a specific release profile.
- A method-of-use patent relevant to the proposed labeling.
- A patent covering a manufacturing process that the applicant practices.
- A listed patent with claims broad enough to reach a generic pellet system.
For a Basic Care private-label product already on the market, the more relevant questions are whether the product is supplied under an approved application, whether the supplier has resolved historical patent disputes, and whether a new formulation or dosage form would create fresh patent exposure.
What patent litigation and settlement agreements affect lansoprazole?
Lansoprazole’s principal patent disputes occurred during the transition from branded Prevacid to generic and OTC competition. The mature product category does not carry the same level of active patent litigation as newer proton-pump inhibitor formulations or combination products.
Historical settlement agreements, if any, must be evaluated by:
- Parties to the agreement.
- Covered dosage forms.
- Authorized launch dates.
- Covenants not to sue.
- Manufacturing restrictions.
- Royalty provisions.
- Whether the agreement covered only a particular generic applicant.
A settlement involving one generic manufacturer does not automatically protect unrelated private-label suppliers. Current litigation status should be checked through PACER, FDA Orange Book records, and the relevant district-court docket. [5][6]
How strong is the patent estate for Basic Care Lansoprazole?
The patent estate is weak as a barrier to conventional generic entry but can be stronger around execution-specific features.
| Asset type |
Estimated barrier for conventional 15 mg capsule |
| Active ingredient patent |
Low |
| Basic delayed-release capsule |
Low to moderate |
| Specific pellet layering process |
Moderate |
| Novel enteric polymer system |
Moderate |
| Improved moisture-stability formulation |
Moderate |
| Sprinkle formulation |
Moderate to high if claims are narrow and active |
| Orally disintegrating formulation |
Moderate to high |
| Pediatric liquid or suspension |
Moderate |
| Packaging and device claims |
Low |
| Trademark and private-label positioning |
Commercial rather than patent protection |
The most defensible technical opportunities are differentiated dosage forms and demonstrable stability improvements. A routine excipient substitution is unlikely to generate strong patent protection unless it produces an unexpected release, stability, bioavailability, or manufacturing result.
What commercial opportunities exist for lansoprazole excipient innovation?
The strongest opportunities are in cost reduction, patient convenience, and supply-chain resilience.
Lower-cost pellet manufacture
A manufacturer can reduce cost through:
- Higher drug-loading efficiency.
- Fewer coating stages.
- Lower coating weight without sacrificing acid resistance.
- Continuous or semi-continuous fluid-bed processing.
- Reduced pellet attrition.
- Standardized excipient sourcing across products.
The commercial value is substantial in private-label retail because the active ingredient is inexpensive and gross margin depends heavily on conversion cost, packaging, freight, and retailer terms.
Gelatin-free capsules
Replacing gelatin with hypromellose or another vegetarian capsule shell can expand the addressable market. The change requires evaluation of moisture transfer, brittleness, machine performance, dissolution, and shelf life.
Sprinkle or easy-open presentations
A capsule that can be opened and sprinkled on soft food may improve use for consumers with swallowing difficulty. The pellets must remain intact and must not be chewed. This format introduces new requirements for labeling, taste, pellet robustness, and dose uniformity.
Reduced-excipient formulations
A simpler excipient system can appeal to consumers seeking fewer colorants, fewer coatings, or allergen-conscious products. The main technical risk is that removing an excipient can destabilize the drug or alter enteric performance.
Improved moisture protection
Lansoprazole products can benefit from high-barrier blister packaging, desiccant-containing bottles, induction seals, and optimized capsule-shell moisture control. Packaging may provide a lower-risk commercial improvement than changing the core pellet formulation.
Combination and adjacent-category products
Commercial expansion could include:
- Lansoprazole with an antacid for rapid symptom relief.
- Lansoprazole paired with an H2 blocker, subject to regulatory and clinical review.
- Travel-size 7-, 14-, or 28-day packages.
- Value packs for recurring heartburn.
- E-commerce multipacks with subscription purchasing.
- Pediatric or swallow-friendly formats, where regulatory requirements permit.
Combination products create greater regulatory and labeling complexity and may attract more patent scrutiny than a standard single-ingredient capsule.
How does lansoprazole compare with omeprazole and esomeprazole?
| Factor |
Lansoprazole |
Omeprazole |
Esomeprazole |
| Drug class |
PPI |
PPI |
PPI |
| OTC presence |
Established |
Very strong |
Strong |
| Compound exclusivity |
Expired |
Expired |
Expired or commercially mature |
| Main dosage forms |
Delayed-release capsule, orally disintegrating formats in some products |
Delayed-release capsule/tablet |
Delayed-release capsule/tablet |
| Retail competition |
High |
Very high |
High |
| Differentiation opportunity |
Pellet engineering and convenience formats |
Broadest value competition |
Brand and efficacy positioning |
| Patent barrier for ordinary OTC product |
Low |
Low |
Low to moderate depending on product |
| Commercial challenge |
Shelf placement and price |
Intense price competition |
Higher consumer price expectations |
Omeprazole has the deepest generic and private-label competition. Lansoprazole can compete through package value, reliable delayed-release performance, capsule convenience, and differentiated excipient positioning.
What generic launch risks exist for Basic Care Lansoprazole?
The principal launch risks are commercial and operational:
- Failure to meet dissolution specifications after accelerated stability testing.
- Inconsistent enteric-coat application.
- Capsule-shell moisture interaction.
- Supplier dependence for specialized enteric polymers.
- Retail price compression.
- Product substitution by lower-priced omeprazole.
- Consumer confusion between immediate symptom relief and delayed PPI action.
- Warning-label or Drug Facts noncompliance.
- Recall risk from capsule or pellet defects.
- Inadequate supply during seasonal or promotional demand.
The risk of a biosimilar challenge is zero because lansoprazole is not a biologic. The risk of a conventional generic competitor is high, but that risk is already reflected in the mature category structure.
What licensing and manufacturing deals matter?
Lansoprazole private-label commercialization commonly depends on supply or licensing arrangements rather than a license to the original compound patent.
Relevant transaction structures include:
- Contract manufacturing of finished capsules.
- Licensing of an approved abbreviated application.
- Supply of coated pellets for encapsulation.
- Private-label manufacturing for a retailer.
- Technology transfer for fluid-bed coating.
- Co-development of sprinkle or capsule-shell variants.
- Exclusive regional distribution agreements.
The most valuable licensable asset is likely to be a validated pellet platform with strong stability data, reliable scale-up, and regulatory support. A basic formulation patent without manufacturing reproducibility has limited commercial value in a low-price OTC category.
What is the revenue exposure and competitive outlook?
Basic Care Lansoprazole operates in a high-volume, low-exclusivity market. Revenue exposure is linked to retailer traffic, search placement, subscription retention, package size, and procurement cost.
The commercial model favors:
- Large-volume manufacturing.
- Low-cost bottles or blister packs.
- Multi-count packages.
- Stable supplier relationships.
- E-commerce replenishment.
- Differentiated consumer claims that remain legally supportable.
- Minimal SKU complexity.
A new entrant should not rely on patent exclusivity to support premium pricing. A defensible business case requires lower landed cost, a meaningful dosage-form advantage, or access to a distribution channel with high repeat demand.
Key Takeaways
- Basic Care Lansoprazole is a mature OTC lansoprazole product, generally sold as a 15 mg delayed-release capsule.
- The active ingredient and original lansoprazole patent estate do not create a meaningful modern exclusivity barrier.
- The central technical challenge is acid protection and reproducible intestinal release.
- Alkaline stabilizers, seal coats, enteric polymers, capsule shells, and moisture-control packaging determine product performance.
- The strongest commercial opportunities are gelatin-free capsules, sprinkle formats, improved stability, lower-cost pellet manufacturing, and optimized packaging.
- Paragraph IV risk is limited for the conventional mature product but can return with new formulations or patented delivery systems.
- Biosimilar risk does not apply.
- The category is commercially attractive only with efficient manufacturing, strong retail distribution, and a clear consumer or supply-chain advantage.
FAQs About Basic Care Lansoprazole
Is Basic Care Lansoprazole the same as Prevacid 24HR?
It contains the same active ingredient, lansoprazole, but products can differ in manufacturer, inactive ingredients, capsule design, packaging, and regulatory application.
Can lansoprazole capsules be reformulated without an enteric coating?
No. Lansoprazole is acid-labile, so a conventional oral product requires a formulation strategy that protects the drug from gastric acid and controls release.
Are lansoprazole excipients patentable?
Yes, a specific excipient combination or manufacturing process can be patentable if it is novel, non-obvious, and adequately supported. Routine substitution of common excipients usually provides weak protection.
Is a lansoprazole private-label product protected by the retailer’s trademark?
Trademark protection can protect the Basic Care brand and trade identity, but it does not prevent competitors from selling legally approved lansoprazole products under different brands.
What is the most commercially attractive new lansoprazole format?
A stable, gelatin-free sprinkle capsule with strong moisture protection offers a clearer differentiation path than another conventional 15 mg delayed-release capsule.
References
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, Prevacid and lansoprazole products. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Over-the-counter human drugs: Acid reducers and proton-pump inhibitors. https://www.fda.gov/drugs/over-counter-otc-nonprescription-medicines
-
National Library of Medicine. (n.d.). DailyMed: Lansoprazole delayed-release capsule labeling. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
-
U.S. Courts. (n.d.). Public Access to Court Electronic Records. https://pacer.uscourts.gov/
